PAXMAN publishes newsletter on the company’s new research centre and the Board of Trade Award received from the British government

Today, PAXMAN publishes the March 2019 issue of its newsletter aimed at shareholders, investors and other interested parties. 

This issue includes articles on the company’s new research centre at Huddersfield University, and the Board of Trade Award that PAXMAN recently received from the British government. Additionally, two large European orders are highlighted in an update on the ongoing order flow.

To read the newsletter, and subscribe to receive upcoming issues, follow this link:

PAXMAN’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on PAXMANs website for investors, The company encourages feedback and requests on topics for upcoming issues of the newsletter. 

For further information, please contact:
Richard Paxman, CEO
Tel: +44 7968 020641

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 3,500 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US)

The PAXMAN share is listed on Nasdaq First North. FNCA Sweden AB is the company’s Certified Adviser and can be contacted via and +46 (0)8 528 003 99.


Documents & Links